Clinical Trial: Kappa Opioid Receptor Imaging in Depression (KOR Depression)

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: Kappa Opioid Receptor Imaging in Depression (KOR Depression)

Brief Summary: The purpose of this study is to use positron emission tomography (PET) imaging to measure the activity of the kappa opioid receptor (KOR) in the brains of depressed and non-depressed individuals.

Detailed Summary: The kappa opioid receptor (KOR) has been implicated in the etiology of fear, threat, and anhedonia in animal models of human depression psychopathology. Herein, we propose to study the KOR in vivo using positron emission tomography, and we will also measure the activity of the hypothalamic-pituitary-adrenal (HPA)-axis in all study participants. We propose to recruit up to N=50 medication-free individuals using a transdiagnostic approach, measure their KOR-selective radioligand [11C]LY2795050 volumes of distribution (VT), an equivalent of KOR availability using positron emission tomography (PET) and study the role of the KOR in mediating the quality and severity of the depressive phenotype.
Sponsor: New York University School of Medicine

Current Primary Outcome: [11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals [ Time Frame: one month ]

To use the KOR radioligand [11C]LY2795050 and PET to examine the relation between KOR availability in the ventral striatum and amygdala, and the full dimensional spectrum of threat and loss symptomatology, and reward responsiveness.


Original Primary Outcome: [11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals [ Time Frame: one month ]

To use the KOR radioligand [11C]LY2795050 and PET to examine the relation between KOR availability in the ventral striatum and amygdala, and the full dimensional spectrum of threat and loss symptomatology, and reward responsiveness.

Hypothesis: Greater [11C]LY2795050 VT values in the ventral striatum will be differentially negatively related to severity of loss (i.e., anhedonia) symptomatology, and positively related to reward responsiveness; greater [11C]LY2795050 VT values in the amygdala, will be differentially negatively related to severity of threat (i.e., anxiety) symptomatology.



Current Secondary Outcome:

Original Secondary Outcome:

Information By: New York University School of Medicine

Dates:
Date Received: September 8, 2014
Date Started: August 2014
Date Completion:
Last Updated: August 15, 2016
Last Verified: August 2016